Simulation of Pooled Nucleic Acid Testing to Identify Antiretroviral Treatment Failure During HIV Infection in Seoul, South Korea by 援щ궓�닔 et al.
Simulation of Pooled Nucleic Acid Testing to Identify
Antiretroviral Treatment Failure During HIV Infection in Seoul,
South Korea
Hyewon Kim, MD*,†, Nam Su Ku, MD*,†, Sun Bean Kim, MD*,†, Su Jin Jeong, MD*,†, Sang
Hoon Han, MD*,†, June Myung Kim, MD, PhD*,†, Davey M. Smith, MD‡,§, and Jun Yong Choi,
MD, PhD*,†
*AIDS Research Institute, Yonsei University College of Medicine, Seoul, South Korea
†Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea
‡Department of Medicine, University of California San Diego, La Jolla, CA
§Veterans Affairs San Diego Healthcare System, San Diego, CA
Monitoring HIV RNA levels (viral loads) every 3–6 months is recommended in patients
receiving antiretroviral therapy (ART) because HIV replication is the most important
indicator of treatment response. In high-resource settings, regular viral load monitoring is a
standard of care1 but not in resource-constrained settings.2 Currently, the number of patients
receiving ART is growing in resource-limited regions and so are the needs for monitoring
for treatment failure and development of drug resistance. Because of the high cost of viral
load testing, virological monitoring has been substituted by clinical and immunologic
monitoring in those regions, but the effectiveness is poor.2,3 There are various efforts to
identify less costly but still accurate method for monitoring treatment response in resource-
limited setting, and a pooling strategy has been proposed.4-7
In theory, pooled testing can decrease the cost of monitoring by reducing the number of
assays needed to screen a population receiving ART,4-7 similar to the pooled nucleic acid
testing (pooled NAT) used to screen for acute HIV infection among individuals presenting
for HIV testing or blood donation.8-10 The usefulness of pooled NAT to detect ART failure
could be affected by several factors, including rate of virologic failure, assay platform, level
of detection, inherent error of assay type, laboratory space to avoid contamination during
processing, and personnel availability and expertise.5 Therefore, studies about use of
pooling NAT for monitoring treatment failure in various circumstances are needed. Three
pooling approaches have been evaluated in previous studies, including minipools, minipool
+ algorithm, and matrix + algorithm.4 Each of these approaches demonstrated a reduction in
the number of assays that need to screen a population receiving ART with minimal decrease
in sensitivity to detect ART failure, that is, “relative efficiency.”4,5 However, relative
efficiency varied by each approach, and the addition of an algorithm for determining the
deconvolution of pools greatly enhanced the relative efficiency. Specifically, the minipool
approach showed the lowest efficiency, and the matrix approach with 8 or 10 pool size was
the most efficient. The minipool + algorithm approach showed intermediated efficiency, and
among them, the one with pool size of 5 samples (5 minipool + algorithm) showed highest
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efficiency. It is also the strategy with the least likely technical errors.4 Based on previous
studies, the matrix + algorithm approach could potentially save more than the minipool +
algorithm, but the matrix platform has been demonstrated to be more technically demanding
with greater chance for contamination.6 Moreover, the matrix approach requires more
samples before testing can be performed, which could lead to longer turnaround time and is
likely not feasible at our institution. Therefore, we pursued evaluation of the minipool +
algorithm approach.
Based on these previously published data and liberally assuming that the accuracy of
minipool + algorithm strategy would be 100%, we calculated at what rate of virologic failure
would the minipool + algorithm strategy demonstrate improvement over testing samples
individually. Specifically, the relative efficiency of the minipool + algorithm would be a
point from “1 − ((1/N) + NR)” to “1 − ((1/N) + R)” [R = rate of virologic failure among the
individual samples, N = number of samples per one pooling test (pool size)]. Accordingly,
the minipool + algorithm approach would be more efficient than individual testing when the
rate of virologic failure (R) is lower than ((1/N) − (1/N2)). As an example, 5 minipool +
algorithm approach could be useful when the virologic failure rate is <16%.
We then performed simulations of a 5 minipool + algorithm strategy using individual viral
load data collected from patients receiving ART for >6 months between January 2009 and
December 2010 at our urban Korean hospital. The viral load assay used (Roche COBAS
AmpliPrep/COBAS TaqMan) has a lower level of detection of 20 HIV RNA copies/mL, and
the cost per assay is 152,970 won (USD $136). Exceeding 200 copies/mL of HIV RNA was
defined as virologic failure according to recent HIV care guidelines.1 In this demonstration
evaluation, both actual individual test and simulated pooled assay were assumed to have no
measurement error; however, viral load values were evaluated based on a gamma
distribution of categories.
During the 24-month period, 1577 viral loads were performed for 351 HIV patients who
were receiving ART for >6 months. The overall virologic failure rate was 9.7% when the
cutoff value of HIV-RNA level was 200 copies/mL, while the distribution of viral loads
(copies/mL) was <20 (85.7%), 20–200 (4.7%), 200–1500 (3.5%), 1500–10,000 (2.2%), 104–
106(3.6%), and >106(0.4%). Based on these data, we selected the 5 minipool + algorithm for
the following simulation.
We arranged the viral load sample data in chronological order assuming that testing would
be performed in order of prescription. Based on the minipool + 5 algorithm, 730 tests were
needed in simulation to screen all samples for ART failure, representing 847 tests saved and
a relative efficiency of 0.54. Converting the tests to cost, a total of USD $115,192 would
have been saved. Since the threshold of viral load for defining treatment failure in our study
was different from the previous study, and the threshold varied by each previous study,4-7
we also investigated the threshold of 1500 copies/mL and found that at 1500 copies/mL, the
virologic failure rate would be reduced from 9.7% to 6.2%, and the subsequent relative
efficiency would be 0.62.
In conclusion, the pooled NAT strategy with 5 minipool + algorithm seems to be a very
promising approach to effectively monitor patients receiving ART and save resources in
South Korea. However, this study was conducted retrospectively and in simulation, so we
could not analyze the turnaround time or accuracy, which could impact the usefulness of this
approach; therefore, a prospectively designed study should be conducted.
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